Skip to main content
. 2024 Feb 10;14(2):e074541. doi: 10.1136/bmjopen-2023-074541

Figure 3.

Figure 3

(A) Changes in high-density lipoprotein cholesterol (HDL-C) in all patients from baseline to the end of the sixth cycle of chemotherapy. (B) Changes in HDL-C in patients with anthracycline-induced subclinical cardiotoxicity (AISC). (C) Changes in HDL-C in patients without AISC.